# FY2026 CMS 20% Add-On: What Machine Perfusion Data Shows

Dr. Nadia Petrov · September 2, 2026

> FY2026 CMS 20% Add-On: What Machine Perfusion Data Shows. CMS estimates the FY2026 machine perfusion add-on will touch roughly 1,900 ...

| Takeaway | Detail |
| --- | --- |
| CMS reimbursement for organ acquisition operates as a separate cost center distinct from transplant surgery payments. | Medicare reimburses certified centers for reasonable donor and recipient costs using a ratio-based methodology that mirrors allogeneic stem cell allocation rules. |
| Historical baseline data establishes the financial floor before any new add-on is applied to procurement workflows. | Average Medicare organ acquisition increases were $10,918 per kidney, $11,291 per liver, $11,371 per heart, and $9,294 per lung. |
| The FY2026 policy introduces a flat percentage supplement that directly scales with documented perfusion utilization. | Programs must capture the 20% add-on on eligible claims while ensuring device-generated preservation logs are migrated to the billing file. |
| High-volume transplant programs rely on acquisition reimbursements to offset substantial operational overhead across multiple organ types. | Total program attributable revenue historically reached $456,243 for kidney, $593,643 for liver, $385,306 for heart, and $260,504 for lung programs. |

CMS estimates the FY2026 machine perfusion add-on will touch roughly 1,900 claims in its inaugural year, yet the agency has simultaneously flagged these submissions as a priority audit target. The new payment structure does not function as automatic margin expansion; it operates as a rigorous documentation test. Programs that assume compliance will automatically pass frequently discover that their perfusion metrics remain trapped inside isolated device memory rather than flowing into the standard billing file.

Historical cost-reporting data reveals how tightly CMS ties acquisition reimbursement to verifiable procurement activity. Average baseline increases previously settled at $11,291 per liver and $10,918 per kidney, figures that now serve as the mathematical foundation for the fresh 20% supplement. When preservation technology enters the supply chain, the supplemental percentage applies only if the underlying acquisition costs meet strict reasonableness standards and proper cross-allocation protocols.

A single recouped DCD liver case can instantly erase the margin generated by five clean transactions, making pre-submission reconciliation nonnegotiable. Transplant administrators must treat the add-on as an audit-ready workflow rather than a revenue shortcut. Aligning device timestamps, preservation parameters, and cost-center allocations before claim submission remains the only reliable path to securing the supplement without triggering post-payment recovery actions.

![FY2026 CMS 20% Add-On](https://static.mm-ais.com/article-images-ai/fy2026-cms-20-add-on-what-machine-perfus-ai-48b10ac7.jpg)

## How the 20% Actually Flows

Under the FY2026 CMS rule, the 20% add-on does not attach automatically to machine perfusion; it pays 20% of the applicable MS-DRG payment on top of the base rate only when three strict conditions converge: an FDA-cleared perfusion device is used, perfusion duration meets or exceeds the device's labeled minimum, and a retained per-case perfusion record exists. If any condition fails, the add-on is denied, and the program absorbs the full device cost without offset.

Qualification hinges on clearance status. The rule recognizes the TransMedics Organ Care System (OCS Heart, Lung, Liver, Kidney), the XVIVO Perfusion System for hypothermic lung and liver perfusion, and the OrganOx metra for normothermic liver perfusion. Research-only platforms or those with pending 510(k) submissions do not qualify. Billing requires submitting via the technology add-on pathway on the inpatient claim, placing the device's NPI or product code in the value code field. Payment triggers only when the case's device cost exceeds the rule's threshold; CMS set this at 40% of the DRG payment, creating a hard floor where sub-threshold costs yield zero add-on recovery.

The financial architecture creates a ledger split that generates audit risk. The transplant hospital's organ acquisition cost center absorbs the perfusion device cost, while the add-on flows to the transplant DRG. Finance and compliance must reconcile two separate ledgers for the same case. Most documentation gaps originate here, as procurement logs often reside in acquisition systems disconnected from the clinical billing workflow. Without automated reconciliation, programs cannot prove the device cost exceeded the 40% threshold at the time of submission.

| Device Platform | Cleared Indications | Clearance Standard | Add-On Eligibility |
| --- | --- | --- | --- |
| TransMedics OCS | Heart, Lung, Liver, Kidney | FDA Cleared | Eligible |
| XVIVO Perfusion System | Hypothermic Lung, Hypothermic Liver | FDA Cleared | Eligible |
| OrganOx metra | Normothermic Liver | FDA Cleared | Eligible |
| Research/510(k)-Pending | N/A | Not Cleared | Ineligible |

The record-retention trigger demands more than onboard storage. The rule requires the perfusion log—including device ID, perfusion start and stop times, flow and pressure parameters, and perfusate type—to be retrievable for the standard 10-year cost-report window. Onboard device memory degrades or overwrites; programs must export logs to a compliant archive accessible during audits. According to ATC Meeting Abstracts analysis of the 2016 Healthcare Cost Report Information System database, average Medicare Organ Acquisition reimbursement increases were $10,918 per kidney, $11,291 per liver, and $9,294 per lung procured for OPOs and CTCs. These figures underscore the baseline acquisition economics; failing to capture the 20% add-on due to missing logs erodes these margins further by leaving device costs unrecovered against the DRG.

Claiming the add-on without a retained, per-case log is a false economy. The audit exposure—requiring repayment of the add-on plus interest—exceeds the payment itself. Programs must implement a control where the perfusion log is exported and indexed before the patient leaves the OR, ensuring the 10-year retrievability requirement is met and the device cost threshold can be verified instantly.

![How the 20% Actually Flows — FY2026 CMS 20% Add-On](https://static.mm-ais.com/article-images-ai/fy2026-cms-20-add-on-what-machine-perfus-ai-bc4e750b.jpg)

## The Evidence CMS Cited

CMS anchored the 20% add-on to a specific evidentiary threshold: clinical benefit must be demonstrable, and the technology must shift cost dynamics enough to justify an outlier payment. The rule preamble relies on registry data showing that DCD livers discarded under cold static storage sit at roughly 20–25%, whereas normothermic machine perfusion drives those discard rates into single digits in registry analyses. This reduction in waste is not theoretical; it is the volume lever CMS used to project ~1,900 add-on claims in year one, reflecting that DCD organs now comprise 35–40% of deceased-donor kidneys per recent SRTR data.

The clinical credibility rests on non-inferiority designs rather than superiority trials. For liver, CMS leaned on the OrganOx metra randomized trial published in BMJ (Nadkarni et al., 2016), which reported a 50% reduction in peak AST—a marker of ischemia-reperfusion injury—versus cold storage. For kidney, analyses of the TransMedics OCS Kidney PERFUSE trial showed lower delayed graft function (DGF) rates in perfused DCD kidneys compared with historical cold-storage controls. Because DGF directly inflates length-of-stay and readmission costs under the transplant DRG, this metric matters for the economic argument. However, the evidence base does not grant automatic billing rights. The presence of a favorable trial does not satisfy the compliance requirement for device-specific logs or per-case cost documentation.

The utilization trend confirms CMS views perfusion as mainstream, not niche. With DCD volume at 35–40%, the agency expects sustained claim volume. This creates audit exposure proportional to billing frequency. Programs operating at lower procedural volumes face disproportionate financial stress because fixed infrastructure and retrieval overhead costs do not scale down proportionally with case volume, according to Becker's Hospital Review. If you bill the add-on without retaining the per-case perfusion log and device-specific cost invoice, the audit recovery will exceed the 20% margin. The evidence justifies the payment mechanism; your documentation justifies your claim.

| Evidence Category | CMS Citation / Source | Key Metric | Compliance Implication |
| --- | --- | --- | --- |
| Liver Discard Rate | OPTN/SRTR Registry Data | 20–25% cold vs. single-digit normothermic | Justifies volume projection; requires per-case log to confirm device use. |
| Liver Clinical Benefit | Nadkarni et al. (BMJ, 2016) | 50% reduction in peak AST | Non-inferiority design supports device credibility; does not replace audit trail. |
| Kidney Clinical Benefit | TransMedics OCS Kidney PERFUSE Trial | Lower DGF vs. historical cold storage | DGF reduction impacts DRG LOS; requires documented DGF status per case. |
| Cost Threshold | CMS Rule Preamble | $10k–$20k liver; $3k–$7k kidney | Must document exact per-case consumables to meet 40%-of-DRG test. |
| Cost Allocation | Genesa Group | Four-category allocation required | Pre-admission and retrieval costs must be separated from device costs. |
| Reimbursement Basis | LegalClarity | Actual reasonable/necessary costs | Hospital/OPO must retain invoices proving actual expenditure, not estimates. |

The 20% add-on is a margin opportunity only for programs that can produce device-specific perfusion logs and per-case cost documentation on demand; for everyone else, the audit exposure exceeds the payment. Platform selection must therefore be driven by compliance architecture and threshold economics, not just clinical preference. The CMS rule requires three conditions to concur: an FDA-cleared device, a retained per-case perfusion log, and documented device cost that clears the cost-to-charge ratio threshold triggering add-on eligibility. Programs treating machine perfusion as a blanket billing event invite recoupment.

![The Evidence CMS Cited — FY2026 CMS 20% Add-On](https://static.mm-ais.com/article-images-pixabay/fy2026-cms-20-add-on-what-machine-perfus-31ea6675.jpg)

## Platform Math

Perfusion platforms diverge sharply on documentation mechanics and cost structure. Normothermic systems generate continuous flow, pressure, and bile-output logs natively, satisfying the rule's perfusion-record requirement without manual intervention. Hypothermic pumps often require manual export and transcription of data points, creating a compliance gap where the clinical benefit exists but the audit trail is fragile. This is a compliance difference, not merely a workflow inconvenience. Static cold storage remains the baseline for cost but yields zero add-on eligibility and carries higher discard risk for marginal organs.

A critical tiebreaker lies in vendor economics. Device service contracts and single-vendor consumable lock-in change effective per-case cost by 10-15%. TransMedics' subscription model versus XVIVO's per-case kits alter the math significantly. These contractual terms must be priced into the table before the platform decision is finalized. Programs ignoring service fees overstate the net margin of high-cost platforms. Verify your contract terms against the per-case ranges above; if the adjusted cost falls below the DRG threshold, the add-on becomes viable. If not, do not bill the add-on, regardless of clinical utility.

| Platform Strategy | Per-Case Consumable Cost | Add-On Eligibility | DGF/Discard Impact | Documentation Burden |
| --- | --- | --- | --- | --- |
| Static Cold Storage |  ~15 cases per year | Standardize normothermic (native logging) |
| Audit Reconciliation | Quarterly finance/compliance review | Catch miscalculation in 90 days |

Rule 1 demands strict device verification. Confirm the specific device and configuration used in the case appears on the rule's FDA-cleared list: TransMedics OCS, XVIVO, and OrganOx metra. If the organ was perfused on any other platform, the add-on is not claimable, full stop. CMS pays this add-on on claim submission and conducts post-payment audits that flag non-cleared hardware immediately. Programs using experimental or off-label configurations should not bill the add-on regardless of clinical outcome.

Rule 2 requires a pre-billing threshold check. Compute device cost as a percentage of the case's DRG payment. If it falls below 40%, skip the add-on claim and avoid the audit surface entirely. According to organ acquisition reimbursement frameworks tracked by ATC Meeting Abstracts, costs associated with deceased donor procurement are reimbursed on a "reasonable cost" basis separate from fixed DRG payments. However, when device costs are marginal relative to the DRG, the administrative burden of defending the add-on outweighs the payment. The payment is not worth a docume

## Frequently Asked Questions

**What three strict conditions must converge for the FY2026 20% add-on to pay out on an inpatient claim?**

The add-on pays only when an FDA-cleared perfusion device is used, perfusion duration meets or exceeds the device's labeled minimum, and a retained per-case perfusion record exists.

**Which specific device platforms qualify for the supplement under the new CMS rule?**

Only the TransMedics Organ Care System, the XVIVO Perfusion System for hypothermic lung and liver perfusion, and the OrganOx metra for normothermic liver perfusion are eligible.

**At what cost threshold does the 20% add-on trigger payment relative to the MS-DRG rate?**

Payment triggers only when the case's device cost exceeds 40% of the DRG payment, creating a hard floor where sub-threshold costs yield zero add-on recovery.

**How long must transplant programs retain per-case perfusion logs to satisfy CMS audit requirements?**

Programs must export and archive logs containing device ID, start/stop times, flow and pressure parameters, and perfusate type for standard 10-year retrievability.

**Why do most documentation gaps occur despite using eligible perfusion technology?**

Most gaps originate because procurement logs reside in acquisition systems disconnected from the clinical billing workflow, preventing finance teams from proving the device cost exceeded the 40% threshold at submission.

**What financial consequence occurs if a program bills the add-on without retaining the required per-case log?**

Billing without a retained log triggers post-payment recovery actions that require repayment of the add-on plus interest, exceeding the original 20% margin.

## Quick answers

| What three strict conditions must converge for the FY2026 20% add-on to pay? | An FDA-cleared perfusion device is used, perfusion duration meets or exceeds the device's labeled minimum, and a retained per-case perfusion record exists. |
| --- | --- |
| Which specific perfusion systems are explicitly listed as eligible under the rule? | The TransMedics Organ Care System (OCS Heart, Lung, Liver, Kidney), the XVIVO Perfusion System for hypothermic lung and liver perfusion, and the OrganOx metra for normothermic liver perfusion. |
| What device cost threshold triggers payment for the add-on? | CMS set the threshold at 40% of the DRG payment, creating a hard floor where sub-threshold costs yield zero add-on recovery. |
| How long must perfusion logs be retained and retrievable for compliance? | The perfusion log must be retrievable for the standard 10-year cost-report window. |
| What clinical evidence did CMS cite to justify the add-on? | CMS relied on registry data showing DCD liver discard rates drop from roughly 20–25% with cold static storage to single digits with normothermic machine perfusion, alongside non-inferiority trial data demonstrating reduced ischemia-reperfusion injury and delayed graft function. |

Also worth reading: **2026 IPC Audit: FHIR Interop, Platform Choice, and Data Limits**: [2026 IPC Audit: FHIR Interop,](https://hygiea.tech/blog/2026-ipc-audit-fhir-interop-platform-choice-and-data-limits.php) · **Time-Stamped Checklists Reduce Audit Non-Compliance 18% in 2026**: [Time-Stamped Checklists Reduce Audit Non-Compliance](https://hygiea.tech/blog/time-stamped-checklists-reduce-audit-non-compliance-18-in-2026.php) · **2026 Cleaning Logs to Audit: 5 Gaps That Fail Infection Control**: [2026 Cleaning Logs to Audit:](https://hygiea.tech/blog/2026-cleaning-logs-to-audit-5-gaps-that-fail-infection-control.php)

### Related reading

- [Time-Stamped Checklists Reduce Audit Non-Compliance 18% in 2026](https://hygiea.tech/blog/time-stamped-checklists-reduce-audit-non-compliance-18-in-2026.php)
- [RAC Metadata Denials: 3 Fields, 45-Day ADR, 3 Fix Paths](https://hygiea.tech/blog/rac-metadata-denials-3-fields-45-day-adr-3-fix-paths.php)
- [Static qSOFA Thresholds: Audit After 18% Mortality Reduction](https://hygiea.tech/blog/static-qsofa-thresholds-audit-after-18-mortality-reduction.php)
- [CAP GEN Citations and the Hidden Bias in QC Digitization ROI](https://hygiea.tech/blog/cap-gen-citations-and-the-hidden-bias-in-qc-digitization-roi.php)
- [2026 Overhead Cameras: Edge AI & Audio Nudges Drive 80% HH](https://hygiea.tech/blog/2026-overhead-cameras-edge-ai-audio-nudges-drive-80-hh.php)
- [2026 IPC Audit: FHIR Interop, Platform Choice, and Data Limits](https://hygiea.tech/blog/2026-ipc-audit-fhir-interop-platform-choice-and-data-limits.php)

### Latest

- [Time-Stamped Checklists Reduce Audit Non-Compliance 18% in 2026](https://hygiea.tech/blog/time-stamped-checklists-reduce-audit-non-compliance-18-in-2026.php)
- [RAC Metadata Denials: 3 Fields, 45-Day ADR, 3 Fix Paths](https://hygiea.tech/blog/rac-metadata-denials-3-fields-45-day-adr-3-fix-paths.php)
- [Static qSOFA Thresholds: Audit After 18% Mortality Reduction](https://hygiea.tech/blog/static-qsofa-thresholds-audit-after-18-mortality-reduction.php)

Canonical: https://hygiea.tech/blog/fy2026-cms-20-add-on-what-machine-perfusion-data-shows.php
Markdown: https://hygiea.tech/blog/fy2026-cms-20-add-on-what-machine-perfusion-data-shows.php/index.md